Zai Lab Limited (ZLAB) Q4 Results: Comparing Essential Metrics Against Analyst Expectations

Zai Lab Limited Reports Fourth Quarter 2025 Financial Results

For the quarter ending December 2025, Zai Lab Limited (ZLAB) announced revenues of $127.6 million, reflecting a 17% increase compared to the same quarter last year. The company posted an earnings per share (EPS) of -$0.46, an improvement from the -$0.80 reported in the previous year’s corresponding period.

Revenue surpassed the Zacks Consensus Estimate of $119.42 million by 6.85%. However, EPS fell short of the consensus estimate of -$0.44, resulting in a negative surprise of 4.55%.

While headline figures like revenue and earnings are closely watched by investors and analysts, a deeper look at key operational metrics can offer more meaningful insights into the company’s performance and future outlook.

Comparing these critical indicators to both analyst forecasts and prior year results can help investors better assess the potential direction of Zai Lab’s stock price.

Key Performance Metrics for the Quarter

• Net Product Revenue: $127.09 million, compared to the three-analyst average estimate of $132.11 million.
• Product Revenue – XACDURO: $10.7 million, exceeding the two-analyst average estimate of $9.6 million.
• Product Revenue – VYVGART: $21.9 million, below the two-analyst average estimate of $39.74 million, representing a 27% year-over-year decline.
• Product Revenue – NUZYRA: $16 million, compared to the two-analyst average estimate of $17.22 million, marking a 45.5% increase from the prior year.
• Collaboration Revenue: $0.51 million, significantly lower than the two-analyst average estimate of $19.34 million.
• Product Revenue – ZEJULA: $56 million, surpassing the two-analyst average estimate of $49.17 million and reflecting a 15.7% increase year over year.

Over the past month, Zai Lab Limited shares have risen by 12.7%, compared to a 0.6% gain in the Zacks S&P 500 composite index. Currently, the stock holds a Zacks Rank #4 (Sell), suggesting it may lag behind the broader market in the near future.

Newly Released: Zacks Top 10 Stocks for 2026

There’s still time to access Zacks’ top 10 stock picks for 2026. Selected by Director of Research Sheraz Mian, this portfolio has delivered impressive and consistent results.

From 2012 through November 2025, the Zacks Top 10 Stocks achieved a remarkable gain of +2,530.8%, far outpacing the S&P 500’s +570.3% return.

Sheraz Mian has reviewed 4,400 companies covered by the Zacks Rank system and identified the 10 most promising stocks to buy and hold in 2026. Be among the first to discover these high-potential picks.

Additional Resources